Immunomic's LAMP Lights Path Toward DNA Vaccines
By Marie Powers
Thursday, March 7, 2013
Privately held Immunomic Therapeutics Inc. (ITI) worked quietly for five years to advance its LAMP-vax technology, based on lysosomal associated membrane protein (LAMP), a ubiquitous glycoprotein found on 80 percent of the surface area of lysosomal membranes.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.